Exposure-Response Analysis of Raltitrexed Assessing Liver Toxicity.

Fiche publication


Date publication

août 2020

Journal

British journal of clinical pharmacology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BORG Christophe, Mme JACQUIN Marion, Dr ROYER Bernard, Dr VERNEREY Dewi, Dr KIM Stephano, Pr SCHMITT Antonin, Dr DEMARCHI Martin, Mme HENRIQUES Julie


Tous les auteurs :
Royer B, Schmitt A, Nguyen T, Paillard MJ, Jary M, Demarchi M, Vernerey D, Henriques J, Jacquin M, Borg C, Kim S

Résumé

Raltitrexed (RTX) is a thymidylate synthase inhibitor with large pharmacokinetics (PK) variability that can be administered in case of 5-fluorouracil (5FU) intolerance or dihydropyrimidine dehydrogenase deficiency (DPD). While it is a more potent thymidylate synthase inhibitor than 5FU, RTX failed to replace this drug for colorectal cancer patients, mainly due to its toxicity at the recommended dose of 3 mg/m every three weeks. However, every two weeks administration at 2 mg/m demonstrated a favourable toxicity profile.

Mots clés

BSA, clearance, dosing rational, population pharmacokinetics, raltitrexed

Référence

Br J Clin Pharmacol. 2020 Aug 12;: